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Abstract
Post-weaning social isolation of rats produces neuroanatomical, neurochemical and behavioral alterations resembling some core
features of schizophrenia. This study examined the ability of the 5-HT6 receptor antagonist SB-399885 to reverse isolation-
induced cognitive deficits, then investigated alterations in hippocampal cell proliferation and hippocampal and frontal cortical
expression of selected intracellular signalingmolecules and cytokines.Male Lister hooded rats (weaned on post-natal days 21–24
and housed individually or in groups of 3–4) received six i.p. injections of vehicle (1% Tween 80, 1 mL/kg) or SB-399885 (5 or
10 mg/kg) over a 2-week period starting 40 days post-weaning, on the days that locomotor activity, novel object discrimination
(NOD), pre-pulse inhibition of acoustic startle and acquisition, retention and extinction of a conditioned freezing response (CFR)
were assessed. Tissue was collected 24 h after the final injection for immunohistochemistry, reverse-phase protein microarray and
western blotting. Isolation rearing impaired NOD and cue-mediated CFR, decreased cell proliferation within the dentate gyrus,
and elevated hippocampal TNFα levels and Cdc42 expression. SB-399885 reversed the NOD deficit and partially normalized
CFR and cell proliferation. These effects were accompanied by altered expression of several members of the c-Jun N-terminal
Kinase (JNK) and p38 MAPK signaling pathways (including TAK1, MKK4 and STAT3). Although JNK and p38 themselves
were unaltered at this time point hippocampal TAK1 expression and phosphorylation correlated with visual recognition memory
in the NOD task. Continued use of this neurodevelopmental model could further elucidate the neurobiology of schizophrenia and
aid assessment of novel therapies for drug-resistant cognitive symptoms.
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Introduction
Schizophrenia has a complex etiology involving genetic and
early-life environmental factors, leading to persistent
neurodevelopmental changes [1]. Conservative estimates sug-
gest the disease affects 5 million people in Europe alone with
an annual cost of almost €94 billion [2]. It is characterized by
positive, negative and cognitive symptoms and although anti-
psychotics are relatively effective in treating the former,
negative and cognitive symptoms remain poorly managed
and prevent reintegration into society [3]. There is conse-
quently a significant demand for novel treatments for these
symptom domains, and reliable predictive animal models are
a tool to improve our understanding of their neurobiology and
evaluation of potential therapeutics.
Social adversity is one environmental influence linked to
human schizophrenia; for example individuals in urban areas
with low social cohesion, or from ethnic minority groups
show a higher incidence, as do those with hearing impairment
(which may result in social isolation or defeat). Parental sep-
aration or loss and abuse or bullying during childhood, fre-
quent relocation during adolescence, and social disadvantage
or exclusion extending into later life have all been identified as
risk factors [4]. Social deprivation can be replicated in rodents
by post-weaning isolation of gregarious rat pups in individual
cages. This neurodevelopmental manipulation produces
* Madeleine V. King
madeleine.king@nottingham.ac.uk
1 School of Life Sciences, Medical School, Queen’s Medical Centre,
The University of Nottingham, Nottingham NG7 2UH, UK
2 School of Medicine, Medical School, Queen’s Medical Centre, The
University of Nottingham, Nottingham NG7 2UH, UK
Molecular Neurobiology
https://doi.org/10.1007/s12035-018-0940-0
lasting neuroanatomical, neurochemical and behavioral alter-
ations which emerge post-puberty and resemble some of the
core features of schizophrenia [5]. Behavioral changes include
hyper-reactivity to novel environments, altered social interac-
tion and increased aggression, and deficits in an array of cog-
nitive tasks reflecting distinct cognitive domains affected by
schizophrenia. These are accompanied by reduced neuronal
plasticity, hyperfunction of mesolimbic and hypofunction of
mesocortical dopaminergic systems, plus altered patterns of
cortical gene expression which suggest disrupted
GABAergic and glutamatergic neurotransmission [5, 6].
There is also evidence for reduced basal extracellular levels
of glutamate in the hippocampus or prefrontal cortex [6, 7]
and altered glutamate receptor antagonist or antipsychotic-
evoked responses in the latter region [8–10].
The aim of the current research was to examine the ability of
a 5 -HT6 recep to r an t agon i s t , N- [3 ,5 -d i ch lo ro -
2-(methoxy)phenyl]-4-(methoxy)-3-(1-piperazinyl)benzene-
sulfonamide (SB-399885), to reverse isolation-induced changes
in a battery of cognitive tasks relevant to deficits in schizophre-
nia [11]; specifically a novel object discrimination (NOD) test
of visual recognition memory, pre-pulse inhibition of the acous-
tic startle response (PPI) which assesses pre-attentional process-
ing and sensorimotor gating, and a conditioned freezing re-
sponse (CFR) paradigm which examines fear-motivated asso-
ciative learning and memory. The 5-HT6 receptor is expressed
in regions involved in learning and memory, including the cor-
tex, hippocampus and amygdala, and selective antagonists ele-
vate glutamate, acetylcholine and dopamine efflux in the rat
prefrontal cortex and/or hippocampus. There is substantial pre-
clinical evidence that they enhance rodent cognitive perfor-
mance across a variety of domains and reverse NMDA receptor
antagonist-induced deficits in pharmacological models of
schizophrenia [12]. Although previous studies have shown re-
versal of isolation-induced deficits in visual recognition mem-
ory by 5-HT6 receptor antagonists [13–15] further evaluation
against a broader array of cognitive deficits in this non-
pharmacological neurodevelopmental model appears justified.
5-HT6 receptor activation stimulates cAMP accumulation
and activates protein kinase A (PKA) via Gαs-coupling, but
interactions with Gαi/o and Gαq [16] and links to ERK1/2 via
Fyn-tyrosine kinase also occur [17–19]. Additional associa-
tions have been identified with Jun activation domain-binding
protein-1 (Jab1) [20], mammalian target of rapamycin com-
plex 1 (mTORC1) and several members of the mTOR path-
way, as well as cyclin-dependent kinase 5 (Cdk5) [14] and
multiple proteins regulating cytoskeleton dynamics [21, 22].
These interactions show enrichment in proteins implicated in
learning and memory, and appear to underlie 5-HT6 receptor-
mediated effects on cell survival, neuronal migration, neurite
growth and dendritic spine morphogenesis [21, 23, 24]; pro-
cesses impaired in neurodevelopmental disorders. To further
characterize isolation-induced molecular changes and their
potential reversal by SB-399885, this study employed a
reverse-phase protein microarray technique [25] to examine
hippocampal and frontal cortical expression and phosphoryla-
tion of selected intracellular signaling molecules (implicated
in cell proliferation, differentiation, migration, apoptosis and
cytoskeletal integrity, and which may modulate learning and
memory), plus immunohistochemistry to examine Ki-67 as a
marker of cell proliferation in the dentate gyrus.
Recent studies reveal decreased plasma IL-4, and increased
IL-1 β, TNFα and IFNγ in isolation-reared rats [26–28].
Similar plasma [29] and prefrontal cortical [30] cytokine al-
terations are reported in schizophrenia, although plasma levels
are influenced by antipsychotic treatment as well as the dis-
ease itself [31]. The potential pathophysiological involvement
of alterations within the brain (where cytokines can act as
neuromodulators as well as inflammatory mediators [32]) re-
mains of interest and may represent a novel therapeutic target
[33]. Animal studies are essential to investigate the roles of
different environmental risk factors in the absence of con-
founding medication status and although most have focused
on models involving direct immune activation it is interesting
that isolation upregulates viral response genes in the hippo-
campus and frontal cortex despite the lack of direct immune
challenge [6, 34]. Peripheral cytokine alterations in this model
are reversed by atypical antipsychotics [27, 28] but possible
brain regional cytokine alterations (and their potential drug
reversal) have received less attention. The final aim of this
study was therefore to use reverse-phase protein microarray
to examine the impact of isolation rearing on hippocampal and
frontal cortical expression of selected cytokines with differing
pro- anti-inflammatory profiles (IL-1β, TNFα IL-6 and IL-
10) and potential reversal of any changes by SB-399885; an
interesting possibility given the 5-HT6 receptor is expressed in
immune tissue [35].
SB-399885 is a potent brain penetrant 5-HT6 receptor an-
tagonist with high affinity for the rat receptor (pKi = 8.81),
200-fold selectivity over all tested receptors, ion channels and
enzymes, as well as a rapid onset (30 min) and long duration
of action (15 h) following oral administration in the rat [36].
The number of animals and duration of testing makes it dif-
ficult to undertake a full dose-response analysis in group-
housed and isolation-reared rats so, consistent with our pre-
vious evaluation of risperidone in this model [37], the current
experiment examined two dose levels (5 and 10 mg/kg i.p.) in
isolates and the highest dose only in group-housed controls.
The pre-treatment time and choice of vehicle were selected
for consistency with other studies in which a 10 mg/kg i.p.
dose was behaviorally active without producing any motor
impairment [38]. A 24-h post-injection time point was select-
ed for tissue collection, as previous studies suggest this is
appropriate for detection of prominent memory-related prote-
omic alterations lasting beyond drug occupancy of Gαs-
coupled receptors [39].
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Materials and Methods
Animals
55 male Lister hooded rats (Biomedical Services Unit,
University of Nottingham, derived from Charles River stock)
were weaned on post-natal day (PND) 21–24 and randomly
assigned to group housing (n = 22; 3–4 per cage) or isolation
(n = 33; 1 per cage), with allocation balanced according to
litter of origin. Animals were housed in plastic cages (32 ×
51 cm for groups and 25 × 42 cm for isolates) containing
sawdust bedding but no environmental enrichment, and main-
tained in the same temperature (21 ± 2 °C) and humidity (55 ±
10%) controlled room on a 12-h light-dark cycle (lights on at
07.00 h) to allow visual, olfactory and auditory contact
throughout the study. Handling was restricted to a singly
weekly cage change and body weight measurement until the
start of behavioral testing, which was conducted during the
light phase (between 09.00 and 17.00 h). The doses and ex-
perimental design (Fig. 1) were chosen to comply with the
three R’s of humane animal testing. All procedures were con-
ducted in accordance with the Animals (Scientific Procedures)
Act, 1986 and the ARRIVE guidelines [40], with approval of
the University of Nottingham Local Ethical Committee.
Drugs and Experimental Protocol
SB-399885 hydrochloride was purchased from Tocris
Bioscience (Bristol, UK) and suspended in 1% aqueous solu-
tion of Tween 80 (Sigma-Aldrich, Dorset, UK) immediately
prior to intraperitoneal (i.p.) administration in a volume of
1 mL/kg. Rats (n = 11 per group) received a total of six injec-
tions of vehicle, 5 or 10 mg/kg SB-399885 (lower dose in
isolates only) over the course of 13 days (40–52 post-
weaning), with a single injection on the days that locomotor
activity, NOD, PPI and acquisition, retention and extinction of
CFR were assessed, using a previously described test battery
and methods with the tasks ordered from least to most aver-
sive [37, 41]. Treatments were administered 30 min prior to
each behavioral test, or immediately after CFR acquisition to
preclude confounding drug effects on nociception [42] or af-
fective state [38]. In all cases, the experimenter was unaware
of the treatment received.
Locomotor Activity
To determine the effect of SB-399885 on isolation-induced
changes in spontaneous motor activity, ambulation and rears
were assessed during a 1-h period in a novel arena on day 40
post-weaning. Thirty minutes after the first injection rats were
placed in individual Perspex boxes (39 × 23.5 × 24.5 cm) with
wire lids, surrounded by a photobeam activity system (San
Diego instruments, CA, USA) consisting of eight parallel
lower beams and four parallel upper beams. A single ambula-
tion count was recorded for every two consecutive adjacent
lower beam breaks, and a single rearing count recorded for
every individual upper beam break.
Novel Object Discrimination
To examine potential reversal of isolation-induced deficits in
visual recognition memory by SB-399885, NOD was
assessed on day 41 or 42 post-weaning, with a balanced mix
of housing and treatment groups on each day. Twenty-six
minutes after their second injection rats were returned to the
same arena used for locomotor activity testing and sequential-
ly received a further 3 min habituation to this arena in the
absence of any objects, 1 min in the home cage, and two
consecutive 3 min object exploration trials separated by a 2-
h inter-trial interval in the home cage. In the first
(familiarization) trial (starting 30 min post-injection), rats en-
countered two identical objects (cylindrical plastic bottles
filled with water and covered in white masking tape, 8 cm
high × 5 cm diameter) and for the second (choice) trial, one
of these objects was randomly replaced with a novel object of
the same size and shape but with four additional horizontal
stripes of black electrical insulating tape. Exploration of each
object, defined as sniffing, licking, chewing or having moving
vibrissae while directing the nose towards and ≤ 1 cm from the
object (but not sitting on an object in the absence of any
directed interest), was recorded separately using stopwatches
and used to calculate the choice trial discrimination ratio (ex-
ploration of the novel object/total choice trial object
exploration).
Pre-pulse Inhibition of Acoustic Startle
To evaluate the effect of isolation rearing and SB-399885 on
sensorimotor gating, PPI was assessed on day 45 post-
weaning. Thirty minutes after the third injection rats were
placed in individual SR-Lab startle response chambers (San
Diego instruments, CA, USA) and received 5 min acclimati-
zation to background white noise (62 dB) then ten 120 dB
(20 ms) startle pulse alone trials. These were followed by a
further 50 startle trials, ten with no pre-pulse and the remain-
der preceded (by 100 ms) with a sub-threshold 72, 76, 80 or
84 dB (40 ms) pre-pulse. These were delivered in a pseudo-
random order with a variable inter-trial interval of 10–20 s,
and were followed by a final five startle alone trials. Individual
whole-body startle responses were recorded for 100 ms from
the onset of each startle pulse and used to calculate a total
cumulative area under the curve (AUC). The mean percentage
PPI for each trial type was calculated from the mean AUC for
that trial type (after using a conditional statement to eliminate
any extreme values greater than two standard deviations away
from the mean, which can result from movement of the rat
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during startle delivery), using the equation % PPI = (pulse
alone AUC – pre-pulse AUC)/pulse alone AUC × 100.
Conditioned Freezing Response
To examine potential reversal of isolation-induced deficits in
associative memory by SB-399885, acquisition, retention and
extinction of CFR were assessed over a 5-day period. On day
48, post-weaning rats were placed into a two-compartment
shuttle box with a light and dark side separated by an auto-
mated door and linked to shuttle box control and shocker units
(Panlab SLab, Barcelona, Spain). After 30 s in the light side,
the door opened and the latency for the animal to transfer to
the dark side was recorded using a floor sensor which also
triggered door closure. After 30 s in the dark side a 5-s con-
ditioned stimulus (light and 3 kHz 89 dB tone) was delivered,
paired with an unconditioned stimulus (1 s × 0.4 mA
footshock delivered through the grid floor) during the last
second. Rats received a total of three stimuli pairings separat-
ed by 55 s and the duration of freezing behavior (immobility,
except for respiration, in a hunched posture with inactive vi-
brissae) following the first two pairings recorded separately
using stopwatches. Immediately after the third pairing rats
were removed from the apparatus and received the fourth
injection of their allocated treatment. Twenty-four hours
(day 49 post-weaning, 30 min after the fifth injection) and
96 h later (day 52 post-weaning, 30 min after the sixth injec-
tion), rats returned to the dark side for a total of 600 s, without
any further footshocks. Freezing to the context was measured
during the first 300 s, then the conditioned stimuli were pre-
sented for 5 s and freezing to cue was measured for the re-
mainder of the trial.
Tissue Collection
Rats were killed 24 h after the final injection (day 53 post-
weaning) by concussion and immediate decapitation and the
right hippocampus and frontal cortex dissected on a refriger-
ated table (4 °C) then frozen in liquid nitrogen (for protein
microarray), while the left hemisphere was cryopreserved in
30% sucrose overnight at 4 °C then frozen in isopentane
cooled by dry ice (for Ki-67 immunohistochemistry).
Samples were stored at − 80 °C until analysis.
Reverse-Phase Protein Microarray
Tissue samples were homogenized at 4 °C in lysis buffer
(20 mM Tris, 1 mM EGTA, 320 mM sucrose, 0.1% Triton
X100, 1 mM NaF, 10 mM B-glycerophosphate in distilled
water adjusted to pH 7.6 with one EDTA-free protease inhib-
itor tablet per 10 mL (Roche Diagnostics, Newhaven, UK);
1 mL per 100 mg wet tissue weight) using a sonic probe
(Soniprep 150: MSE Scientific Instruments, Crawley, UK;
10 s) and vertical rotator (Bibby Scientific, Stone, UK;
30 min, 4 °C), then centrifuged (3300g; Sigma 3-18 k:
Newtown, UK; 5 min, 4 °C). Proteins in the supernatant were
quantified by Lowry assay [43] and solubilized by addition of
solubilization buffer (to achieve final concentrations of 4%
SDS, 5% glycerol, 5% β-mercaptoethanol, 0.01%
bromophenol blue and 0.0625 M Tris HCl), heated to 95 °C
for 1 min, vortexed briefly, centrifuged (13,400g; Eppendorf
5417R: Stevenage, UK; 1 min) then adjusted to protein con-
centrations of 2 μg/μL. Samples were further diluted to
1.5 μg/μL using 4 × SDS buffer containing 10% β-
mercaptoethanol and 5 units/mL benzonase) and the
heat/vortex/centrifuge procedure repeated before spotting on-
to nitrocellulose-coated glass slides (Grace Bio-Labs, Bend,
Oregon, USA) at 1.5, 0.75 and 0.375 μg/μL with a
microarrayer (MicroGridII; Digilab, Marlborough, MA,
USA). They were blocked overnight (4 °C with constant
rocking) in 0.2% I-block (Tropix, Bedford, MA, USA),
0.1% Tween 20 in phosphate-buffered saline (TBST), then
washed three times with TBST. Hippocampal slides were in-
cubated overnight (4 °C with constant rocking) with one of 37
Fig. 1 Summary of the experimental protocol. Fifty-five male Lister
hooded rats were maintained in social groups of 3–4 (Gr) or isolation
(Iso) from weaning on post-natal day (PND) 21–24. They received a
total of six i.p. injections of vehicle (1% Tween 80 1 mL/kg), 5 or
10 mg/kg SB-399885 (lower dose in isolates only) over a 13-day
period, on the days that locomotor activity (LMA), novel object
discrimination (NOD), pre-pulse inhibition of acoustic startle (PPI),
acquisition (acq) of a conditioned freezing response (CFR) and its
retention (ret) 24 and 96 h later were examined. Behavioral tests were
ordered from least to most aversive and treatments were administered
30 min prior to each, or immediately after CFR acquisition. Rats were
killed 24 h after the final injection and brain tissue samples collected for
reverse -phase pro te in microar ray, wes te rn b lo t t ing and
immunohistochemistry (n = 11 per housing-treatment combination)
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rabbit primary antibodies for proteins involved in PI3K/Akt,
Erk, JNK, p38 MAP kinase, or Wnt/β-Catenin signaling, en-
vironmental stress and MAPK scaffolding (Cell Signaling
Technology, Danvers, MA, USA; Table 1), or one of four goat
primary antibodies for rat cytokines (R&D Systems,
Minneapolis, MN, USA; Table 1), plus mouse β-actin prima-
ry antibody (1:1000; Sigma). Frontal cortical analysis was
restricted to four JNK signaling intermediates which showed
the greatest alteration in the hippocampus, plus the same four
cytokines. Slides were washed, incubated in the dark for
30 min (room temperature with constant rocking) with 680
CW anti-mouse and 800 CW anti-rabbit infrared secondary
antibodies (1:5000; LI-COR, Cambridge, UK), washed and
then dried by centrifugation at 500×g for 5 min. Slides were
scanned using a LI-COR Odyssey system (Cambridge, UK)
and resultant TIFF images were processed with Axon
Genepix Pro-6 Microarray Image Analysis software
(Molecular Devices, Berkshire, UK) to obtain fluorescence
data for each feature and generate gpr files. Protein signals
were determined with background subtraction and normalized
to β-actin expression using RPPanalyzer (German Cancer
Research Centre, Heidelberg, Germany) [44]. Previous vali-
dation studies confirmed the selectivity of all primary antibod-
ies, which detected single bands of the appropriate molecular
weight on strip westerns [25 and unpublished observations]. It
was not possible to measure all intermediates of the selected
signaling pathways where suitable antibodies for microarray
have yet to be validated, and quantification of these proteins
was therefore beyond the scope of the current study.
Western Blotting
Significant changes in combined Rac1 and Cdc42 expression
were detected by reverse-phase protein microarray but the
antibody used was unable to differentiate between these pro-
teins or their total versus phosphorylated states. Western blots
were therefore performed using separate antibodies, both to
validate that reverse-phase protein microarray data could be
replicated with an alternative technique, and to provide further
insight into altered Rho-GTPase expression and activation.
Samples (2 μg protein/μl) were loaded (16 μg protein per
lane) onto Mini-PROTEAN TGX gels (Bio-Rad, Watford,
UK), separated (150 V for 1 h) then transferred to nitrocellu-
lose membranes (100V for 1 h at 4 °C) and blocked with a 5%
milk solution (dried milk powder dissolved in Tris-buffered
saline containing 5% Tween 20 (TBST); 1 h at room temper-
ature). Portions containing proteins < 25 kDa were incubated
overnight (at 4 °C) with rabbit polyclonal primary antibodies
against Rac1 (1:500), p-Rac1 (Ser71, 1:500), Cdc42 (1:250;
all Abcam, Cambridge, UK), or p-Cdc42 (Ser71, 1:150;
Biorbyt Ltd., Cambridge, UK). Corresponding portions con-
taining proteins > 25 kDa were incubated with rabbit poly-
clonal primary antibodies against the housekeeping protein
GAPDH (1:20,000; Sigma-Aldrich, Dorset , UK).
Membranes were washed three times with TBST, incubated
Table 1 Primary antibodies used for reverse-phase protein microarray
analysis
Pathway Protein Antibody
dilution
Intracellular signaling proteins
PI3K/Akt signaling PI3K p85 1:500
PI3K p110α 1:250
PTEN 1:500
p-PTEN (Ser380) 1:500
p-PDK1 (Ser241) 1:1000
p-Akt (Thr308) 1:50
p-Akt (Ser473) 1:25
p-Bad (Ser136) 1:250
Erk signaling SHP-2 1:250
c-Raf 1:500
p-c-Raf (Ser259) 1:500
MEK1 and MEK2 1:500
Erk1/2 1:1000
p-Erk1/2 (Thr202/Tyr204) 1:1000
JNK and/or p38
MAP
kinase signaling
Rac1 and Cdc42 1:500
p-MKK3 and p-MKK6
(Ser189/207)
1:250
MKK4 1:250
p-MKK4 (Thr261) 1:250
MKK7 1:250
TAK1 1:250
p-TAK1 (Ser412) 1:250
JNK 1:1000
p-JNK (Thr183/Tyr185) 1:1000
p38 MAPK 1:1000
p-p38 MAPK (Thr180/Tyr182) 1:1000
14–3-3ε 1:250
p-HSP27 (Ser82) 1:50
p-c-Jun (Ser63) 1:250
p-ATF-2 (Thr71) 1:250
p-Elk-1 (Ser383) 1:250
STAT3 1:500
p-STAT3 (Tyr705) 1:100
Wnt/β-catenin
signaling
GSK-3β 1:500
p-GSK-3β (Ser9) 1:500
β-Catenin 1:250
Environmental stress HSP90 1:1000
MAPK scaffolding Flotillin-1 1:250
Cytokines
IL-1β 1:500
IL-6 1:500
IL-10 1:1000
TNFα 1:1000
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in the dark for 1 h with 800 CWanti-rabbit infrared secondary
antibodies (1:10,000; LI-COR, Cambridge, UK) then washed
a further three times with TBST. Protein bands were detected
and quantified using a LI-COR Odyssey system (Cambridge,
UK) and data expressed as a percentage of GAPDH
expression.
Ki-67 Immunohistochemistry
Brains from 24 representative animals from group-housed and
isolation-reared vehicle and 10 mg/kg SB-399885 treatment
groups (n = 6 per group) were embedded in OCT (VWR
International Ltd., Lutterworth, UK) at − 20 °C and serially
sectioned in the coronal plane using a Leica CM 100 cryostat
(Leica Microsystems, Knowlhill, UK). Sections were thaw-
mounted onto 3-aminopropylmethoxysaline (APES)-coated
slides and stored at − 20 °C until use. Ten sections from each
rat, evenly spaced throughout the dentate gyrus, were chosen
for Ki-67 immunohistochemistry and underwent the follow-
ing protocol at room temperature in light-proof humidified
chamber. Sections were fixed in 0.5% paraformaldehyde for
3 min and washed three times in PBS (5 min each), before 1 h
incubation with monoclonal mouse Ki-67 primary antibody
(1:100; Vector Laboratories, Peterborough, UK). Sections
were washed, incubated for 1 h with Alexa Fluor 488 goat
anti-mouse IgG3 secondary antibody (1:300; Invitrogen,
Paisley, UK), washed again and counterstained with DAPI
nuclear stain using Vectashield hard set mounting medium
(Vector Laboratories, Peterborough, UK) then cover-slipped.
Slides were stored at 4 °C and viewed at × 40 on a Nikon
EFD-3 fluorescence microscope. The number of Ki-67 posi-
tive cells (discerned by co-localization of Ki-67 and DAPI
staining) within the granular cell layer of the entire dentate
gyrus and the sub-granular zone (defined as within a two cell
layer of the granular cell layer on the hilar edge) were counted
to provide a total value for the ten evenly spaced sections from
each animal.
Statistical Analysis
All analyses were performed using GraphPad Prism (v6.04) or
IBM SPSS (v21) which can accommodate the unbalanced
design caused by the lack of low dose SB-399885 evaluation
in group-housed rats. Behavioral data were analyzed by three-
way repeated measures ANOVAwith time (locomotor activi-
ty), object (NOD), pre-pulse volume (PPI) or context/cue
(CFR) as the within-subject factor and housing and treatment
as between-subject factors. The NOD choice trial discrimina-
tion ratio, protein expression data and Ki-67 positive cell
counts were analyzed by two-way ANOVA with housing
and treatment as between-subject factors. ANOVAs were
followed by Sidak post hoc tests with planned multiple com-
parisons (group-housed vehicle versus group-housed 10 mg/
kg SB-399885, group-housed vehicle versus isolation-reared
vehicle, isolation-reared vehicle versus isolation-reared 5 mg/
kg SB-399885, isolation-reared vehicle versus isolation-
reared 10 mg/kg SB-399885, and group-housed 10 mg/kg
SB-399885 versus isolation-reared 10 mg/kg SB-399885)
and P < 0.05 was regarded as statistically significant. Data
are presented as the mean ± s.e.m. Visual representation of
protein expression data in the form of a heat map was pro-
duced using Heatmapper software [45], and additional
Pearson’s r correlation analyses were performed between sig-
naling intermediates or cytokines significantly influenced by
housing and/or treatment and locomotor activity (as indicated
by total ambulatory activity in the first 35 min of the session),
cognitive performance in NOD and CFR tasks (as indicated
by the choice trial discrimination ratio and cued freezing 24 h
post-acquisition, respectively) and Ki-67 positive cell counts.
Results
Locomotor Activity
Housing and treatment both influenced ambulatory activity
during a 1-h period in a novel arena (time × housing
F(11,550) = 3.939, P ≤ 0.001, time × treatment F(22,550) =
2.032, P ≤ 0.01). Ambulation was higher in vehicle-treated
isolates than group-housed controls at the 10 min time point
only (P < 0.05) but showed a prolonged decrease by SB-
399885 irrespective of housing. Because all the observed
between-group differences were in the first 35 min of the
session (Fig. 2a), total activity counts during this period were
also studied. Total ambulation was decreased by SB-399885
(F(2,50) = 18.064, P ≤ 0.001; 5 mg/kg P < 0.05 and 10 mg/kg
P < 0.001 versus relevant vehicle control), with the effect of
housing just failing to reach significance (F(1,50) = 3.516, P =
0.067) (Fig. 2b). Total rearing was decreased to a lesser extent
by SB-399885 (F(2,50) = 8.714, P ≤ 0.001; 10 mg/kg P < 0.05
versus vehicle) but in this case there was a main effect of
housing (F(1,50) = 4.169, P ≤ 0.05) (Fig. 2c).
Novel Object Discrimination
There were no spatial preferences for either identical object
during the familiarization trial (data not shown), although the
highest dose of SB-399885 decreased total levels of object
exploration by isolation-reared rats (P < 0.01) in this trial
alone (group-housed vehicle 49 ± 6 s, group-housed SB-
399885 34 ± 4 s, isolation-reared vehicle 59 ± 5 s, isolation-
reared 5 mg/kg SB-399885 45 ± 7 s, isolation-reared 10mg/kg
SB-399885 28 ± 6 s). In the choice trial (2 h later), there was a
housing × treatment × object interaction (F(1,50) = 5.907, P ≤
0.05). Group-housed control animals were able to successfully
discriminate the novel from the familiar object (P < 0.0001)
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and administration of SB-399885 to group-housed animals
did not alter this. However, vehicle-treated isolates were un-
able to discriminate the novel object (P > 0.05) and this deficit
was reversed by SB-399885 (P < 0.001 at 5 and P < 0.0001 at
10 mg/kg; Fig. 3). Importantly, this redistribution of object
exploration occurred without any difference in total choice
trial object exploration, and differences in cognitive perfor-
mance during the choice trial cannot be explained by the pat-
tern of altered object exploration during the familiarization
trial or ‘learning phase’ of the task.
Pre-pulse Inhibition of Acoustic Startle
Although all rats demonstrated the normal increase in percent
PPI with increasing pre-pulse volume (F(3,150) = 69.569, P ≤
0.0001), this was not influenced by housing or treatment.
There were no differences in basal startle reactivity or habitu-
ation to the startle pulse across the test session (data not
shown).
Conditioned Freezing Response
There were no between-group differences in acquisition of the
CFR (data not shown). On re-exposure to the apparatus 24 h
later (in the absence of footshocks), there was a context/cue ×
housing interaction (F(1,50) = 10.313, P ≤ 0.01), and while nei-
ther treatment or housing altered freezing to the context
(Fig. 4), there was a main effect of housing on freezing to
the cue (F(1,50) = 13.626, P ≤ 0.001). Isolation rearing reduced
this duration in vehicle-treated animals (P < 0.05 versus
group-housed control) and although not fully reversed by
SB-399885, post hoc comparison of each group to every other
revealed the isolation-induced deficit was absent following
drug treatment (P > 0.05; Fig. 4). On further return to the
apparatus 96 h post-acquisition, there were reductions in
freezing to context (F(1,50) = 117.3, P ≤ 0.0001) and cue
(F(1,50) = 41.51, P ≤ 0.0001), consistent with extinction in the
absence of further footshocks. At the 96 h time point, there
Fig. 2 Effect of isolation rearing and SB-399885 on locomotor activity in
a novel arena. Mean ± s.e.m. number of infrared beam breaks for a
timecourse of ambulatory activity across the 1 h monitoring period and
b total ambulation and c total rears within the first 35 min of the session.
Group-housed (Gr) and isolation-reared (Iso) male Lister hooded rats
received the first of six i.p. injections of vehicle (1% Tween 80 1 mL/
kg), 5 or 10 mg/kg SB-399885 (lower dose in isolates only) 30 min prior
to the start of the test session on day 40 post-weaning (n = 11 per group).
**P < 0.01; ***P < 0.001; ****P < 0.0001 Gr10 versus GrV, +P < 0.05
Iso5 versus IsoV, #P < 0.05; ##P < 0.01 Iso10 versus IsoV, †P < 0.05 IsoV
versus GrV (three-way repeated measures ANOVA (a) or two-way
ANOVA (b, c) with Sidak planned multiple post hoc comparisons)
Fig. 3 Effect of isolation rearing and SB-399885 on novel object
discrimination following a 2-h inter-trial interval. Mean ± s.e.m. time (s)
spent exploring the novel and familiar object during the choice trial.
Group-housed (Gr) and isolation-reared (Iso) male Lister hooded rats
received the second of six i.p. injections of vehicle (1% Tween 80
1 mL/kg), 5 or 10 mg/kg SB-399885 (lower dose in isolates only)
30 min prior to the start of the familiarization trial on day 41 or 42 post-
weaning (n = 11 per group). ***P < 0.001; ****P < 0.0001 versus the
familiar object in the same group of rats (three-way repeated measures
ANOVAwith Sidak post hoc test)
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was no context/cue × housing interaction nor any between-
group differences in the level of extinction (data not shown).
Reverse-Phase Protein Microarray and Western
Blotting
Visual representation in the form of a heat map revealed
four broadly clustered groups of proteins (Fig. 5) whose
general qualitative pattern appeared to be: similar or in-
creased in isolates compared to group-housed controls,
but decreased by the highest dose of SB-399885 (mainly
components of JNK and/or p38 MAPK pathways); de-
creased by isolation, but increased by the lowest dose of
SB-399885 (several members of the PI3K/Akt cascade);
decreased by both does of SB-399885 (a small number of
proteins from a range of pathways); similar or elevated in
isolates compared to group-housed controls, and highest
in isolates treated with the highest dose of SB-399885
(components of JNK and/or p38 MAPK pathways plus
the majority of cytokines). Subsequent statistical analyses
confirmed several significant changes, most of which
were only apparent at the main effect level. In the hippo-
campus, these include effects of housing on TNFα
(F(1,50) = 4.300, P ≤ 0.05) and treatment on the negative
PI3K/Akt regulator PTEN (F(2,50) = 3.714, P ≤ 0.05), with
similar trends for PI3K 110α, p-Akt (Thr308)) and Erk1/2
(F(2,50) = 2.775, P = 0.073; F(2,50) = 2.794, P = 0.071 and
F(2,50) = 2.639, P = 0.082 respectively), and a housing ×
treatment interaction for IL-1β (F(1,50) = 4.120, P ≤ 0.05).
There was also housing effect on the proportion of the
multifunctional kinase TAK1 in the phosphorylated (Ser412)
state within the frontal cortex (F(1,50) = 5.086, P ≤ 0.05).
More robust alterations were observed for a limited number
of proteins associated with JNK and/or p38 MAP kinase sig-
naling. These include an effect of housing on combined hip-
pocampal levels of the Rho-GTPases Rac1 and Cdc42
(F(1,50) = 12.561, P ≤ 0.001), which represented the greatest
expression change in this study (Fig. 5). Values obtained by
reverse-phase protein microarray were over 25% higher in
isolates than group-reared rats following the highest dose of
SB-399885 (P < 0.05; Fig. 6a). This housing effect was con-
firmed with different antibodies via the complimentary tech-
nique of western blotting (F(1,50) = 9.688, P ≤ 0.01; Fig. 6a)
and expression levels for individual animals showed a signif-
icant positive correlation between the two approaches (P =
0.0333). Greater selectivity of the western blot antibodies
allowed attribution of the isolation-induced increase to total
Cdc42 (F(1,50) = 5.489, P ≤ 0.05; Fig. 6b), with decreases of
over 40% in p-Cdc42 (F(1,50) = 5.021, P ≤ 0.05; Fig. 6b) and
over 70% in the proportion of cdc42 in the phosphorylated
(Ser71) state (F(1,50) = 9.497, P ≤ 0.01; Fig. 6b) while Rac1
remained unaffected. There was a housing × treatment inter-
action for hippocampal TAK1 (F(1,50) = 4.578, P ≤ 0.05)
which showed a small but significant decrease following ad-
ministration of the highest dose of SB-399885 to isolation-
reared rats (P ≤ 0.05 versus isolate vehicle; Fig. 6c), resulting
in a further housing × treatment interaction for the proportion
of TAK1 in the phosphorylated state (F(1,50) = 5.476, P ≤ 0.05;
Fig. 6c). SB-399885 had a main effect on total expression of
the dual specificity kinase MKK4, which activates JNK and
p38, and showed a small but significant increase (F(2,50) =
3.770, P ≤ 0.05) of 16% in the frontal cortex following admin-
istration of the highest dose to isolation-reared rats (P ≤ 0.05
versus isolate vehicle; Fig. 6d). There were also effects of
housing (F(1,50) = 5.109, P ≤ 0.05) and treatment (F(2,50) =
4.383, P ≤ 0.05) on the proportion of hippocampal MKK4 in
the phosphorylated (Thr261) state, but the increase following
administration of the highest dose to isolation-reared rats just
missed the threshold for statistical significance (P = 0.0638;
Fig. 5). Although at this time point hippocampal expression
and phosphorylation of JNK itself appeared to be unaffected,
there were housing × treatment interactions for expression
(F(1,50) = 4.358, P ≤ 0.05) and phosphorylation (Tyr705)
(F(1,50) = 6.249, P ≤ 0.05) of the downstream nuclear target
STAT3 such that proportion in the phosphorylated state
remained constant (Fig. 5).
Ki-67 Immunohistochemistry
There was a main effect of housing on the number of Ki-67
positive cells in the dentate gyrus (F(1,20) = 7.415, P ≤ 0.05).
Isolation rearing decreased the Ki-67 positive cell count in
vehicle-treated rats (P < 0.05 versus group-housed), and
Fig. 4 Effect of isolation rearing and SB-399885 on retention of a
conditioned freezing response 24 h after the acquisition trial. Mean ±
s.e.m. duration (s) of freezing to context in the 5 min period before, and
freezing to cue in the 5 min period immediately after a 5-s tone and light
presentation in the absence of further footshocks. Group-housed (Gr) and
isolation-reared (Iso) male Lister hooded rats received the fifth of six i.p.
injections of vehicle (1% Tween 80 1 mL/kg), 5 or 10 mg/kg SB-399885
(lower dose in isolates only) 30 min prior to the start of the test session on
day 49 post-weaning (n = 11 per group). †P < 0.05 versus the same
treatment and freezing condition in group-housed rats (three-way
repeated measures ANOVA with Sidak planned multiple post hoc
comparisons)
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10 mg/kg SB-399885 appeared to partially reverse this
isolation-induced decrease since it was absent following drug
treatment (P > 0.05 versus isolate vehicle but also P > 0.05
versus group-housed vehicle; Fig. 7).
Correlation Analyses
Correlation analyses between behavioral performance or hip-
pocampal cell proliferation and signaling intermediates or cy-
tokines significantly influenced by housing and/or treatment
revealed a negative association of hippocampal TAK1 with
visual recognition memory in the NOD task, as indicated by
the choice trial discrimination ratio (P = 0.0071; data not
shown). There were positive relationships between NOD
and hippocampal p-TAK1 (Ser412) as a proportion of total
(P = 0.0056; Fig. 8a), hippocampal IL-1β (P = 0.0404;
Fig. 8b) and frontal cortical p-MKK4 (Thr261) (P = 0.0459;
Fig. 8c), together with a negative relationship between hippo-
campal MKK4 and Ki-67 positive cell count (P = 0.0485;
Fig. 8d).
Discussion
Post-weaning isolation of rats produces lasting neuroanatom-
ical, neurochemical and behavioral alterations which emerge
post-puberty, resemble some of the core features of schizo-
phrenia, and offer the potential to detect reversal by novel
Fig. 5 Effect of isolation rearing and SB-399885 on hippocampal and
frontal cortical expression of signaling intermediates and cytokines. Blue
(low) to red (high) signal intensity heat map representing the mean
percentage difference in expression following each housing-treatment
combination from the overall mean expression of that protein in the
study as a whole; proteins are in the hippocampus unless prefixed by
the frontal cortex (FCtx) abbreviation. Group-housed (Gr) and isolation-
reared (Iso) male Lister hooded rats received a total of six i.p. injections of
vehicle (1% Tween 80 1 mL/kg), 5 or 10 mg/kg SB-399885 (lower dose
in isolates only) over a 13-day period, and were killed 24 h after the final
injection (n = 11 per group). Statistical analyses were performed on the
raw data (i.e., expression as a percentage of β-actin in the same
individual), not differences from the overall study mean. †P < 0.05 main
effect of housing; *P < 0.05; ***P < 0.001 main effect of treatment;
#P < 0.05 housing × treatment interaction; symbols in parentheses
indicate respective effects on the proportion in the phosphorylated state
(two-way ANOVA; for significance with Sidak plannedmultiple post hoc
comparisons see Fig. 6)
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agents operating on diverse pharmacological mechanisms.
Although 5-HT6 receptor antagonists prolong memory in nor-
mal animals and reverse a variety of pharmacological deficits,
their effects in relevant neurodevelopmental models are less
well characterized. In addition to supporting known links to
PI3K/Akt [14] and Erk1/2 [17–19] signaling and replicating
reversal of isolation-induced recognition memory deficits [13,
15] with a structurally unrelated antagonist, this study pro-
vides the first evidence for potential modulation of associative
memory and cell proliferation within the dentate gyrus in this
model, and is also the first to reveal downstream effects of a 5-
HT6 receptor antagonist on members of the JNK signaling
pathway. The reverse-phase protein microarray technique pro-
vides a more direct functional measure than RNA analysis,
and has previously been employed to study allergy [46], in-
flammation [47], cancer [48] and tumor necrosis factor
receptor-associated periodic syndrome (TRAPS) [25, 49], al-
though its current application to neurodevelopmental disor-
ders and neuropharmacology is relatively novel.
5-HT6 receptor antagonists [50] including SB-399885 [38]
can decrease locomotor activity and doses were therefore se-
lected from the literature to avoid sedation. Previous studies
Fig. 6 Effect of isolation rearing and SB-399885 on hippocampal and
frontal cortical expression of selected JNK and/or p38 MAP kinase
signaling intermediates. a Representative western blots, plus bar graph
comparison of mean ± s.e.m. combined Rac1 and Cdc42 expression in
the hippocampus using reverse-phase proteinmicroarray and western blot
analyses. Reverse-phase protein microarray data (solid bars) are
expressed as a percentage of β-actin and shown on the left-hand y-axis,
and western blot data (diagonal shaded bars) are expressed as a
percentage of GAPDH and shown on the right-hand y-axis. b
Representative blots and bar graph of mean ± s.e.m. hippocampal
Cdc42 and p-Cdc42 (Ser71), quantified by western blotting and
expressed as a percentage of GAPDH. Remaining bar graphs show
reverse-phase protein microarray quantification of mean ± s.e.m. c
Hippocampal TAK1 and p-TAK1 (Ser412) and d frontal cortical
MKK4 and p-MKK4 (Thr261), all as percentages of β-actin. Group-
housed (Gr) and isolation-reared (Iso) male Lister hooded rats received
a total of six i.p. injections of vehicle (1% Tween 80 1 mL/kg), 5 or
10 mg/kg SB-399885 (lower dose in isolates only) over a 13-day
period, and were killed 24 h after the final injection (n = 11 per group).
*P < 0.05 versus vehicle under the same housing condition, †P < 0.05
versus the same treatment in group-housed rats (two-way ANOVAwith
Sidak planned multiple post hoc comparisons)
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[38, 51, 52] used Wistar rats and although some non-selective
decrease in ambulation was observed here on first administra-
tion to Lister hooded rats (rather than the selective reversal of
isolation-induced hyperactivity produced by anmGluR2/3 ag-
onist [53]), it is important to emphasize that the subsequent
effects of SB-399885 on cognition and Ki-67 expression can-
not simply be attributed to locomotor confounds. In the NOD
task, for example, isolation impaired choice trial discrimina-
tion without reducing total object exploration during the fa-
miliarization trial or ‘learning phase’ of the paradigm, and SB-
399885 reversed this isolation-induced deficit despite having
decreasing familiarization trial object exploration. Likewise
any transient isolation-induced locomotor hyperactivity did
not prevent expression of the CFR during acquisition training
or contextual phases of the retention trials so would be an
unlikely explanation for reduced cued freezing in these ani-
mals, and any potential sedative-type decrease in activity fol-
lowing SB-399885 would not confound scoring of freezing
behavior with a hunched (rather than relaxed) body posture.
Locomotor hyperactivity in isolation-reared rats has been
attributed to sensitization of the mesolimbic dopaminergic
pathway [54–56] but the transient nature of this hyperactivity
in the current study, together with the locomotor effect of SB-
399885 in group-housed rats precludes any firm conclusions
on drug-induced normalization of the housing effect.
Likewise the lack of an isolation-induced PPI deficit in the
current study (which may be related to strain and/or weaning
age [57, 58]) prevented any evaluation of potential reversal by
SB-399885, but other recent studies have just revealed that
chronic 5-HT6 receptor antagonist administration can restore
PPI in isolation-reared Wister rats [15] and may have some
adjunctive benefit against the positive symptoms in female
patient sub-groups [59].
5-HT6 receptor antagonists prolong visual recognition
memory in normal animals and reverse NOD deficits in a
variety of pharmacological models [12], and these effects are
maintained following isolation rearing. NOD impairments in
this model are reversed by compounds acting through diverse
mechanisms, including the atypical antipsychotics clozapine
and risperidone, an mGluR2/3 agonist, and antagonists of
CB1, dopamine D3 and α2C adrenoceptors [28, 37, 53,
60–62]. Clinical evaluation of receptor-selective compounds
on visual learning and memory in schizophrenia is still
awaited, but modest effects of clozapine and risperidone [63,
64] appear to support the predictive validity of NOD in con-
junction with the isolation rearing model. Glutamate
hypofunction in the dorsal hippocampus is sufficient to impair
NOD [65] so isolation-induced glutamatergic changes [7] in-
cluding reduced VGLUT1 expression [66] may underlie this
particular cognitive deficit. Unpublished microdialysis data
from our laboratory reveal that isolation attenuates choice trial
dopamine efflux from the prefrontal cortex; a key site for the
NOD effects of D3 receptor antagonists [67] which increase
dopamine efflux [68]. Elevation of hippocampal glutamate
[69] and/or prefrontal cortical dopamine [70] efflux therefore
represent plausible mechanisms via which 5-HT6 receptor an-
tagonists could overcome isolation-induced NOD deficits, al-
though further studies are required to determine whether these
neurochemical effects are maintained following isolation.
Interactions with mTOR signaling (which is disrupted in
schizophrenia and by environmental factors [71]) appear rel-
evant [14] and novel findings from the current study demon-
strate hippocampal (but not frontal cortical) TAK1 expression
and activation correlate with NOD, as do hippocampal IL-1β
and frontal cortical p-MKK4. Although this does not neces-
sarily prove a causal relationship recent studies show TAK1
expression is increased during acquisition, consolidation and
retrieval of contextual fear memory [72], and implicated in the
cognitive effects of GSK-3β inhibitors in a stroke model [73],
while IL-1β can have positive effects on hippocampal-
dependent memory [74, 75]. The potential association of hip-
pocampal TAK1 and cytokines with visual recognition mem-
ory should be further investigated by intra-hippocampal ad-
ministration of 5-HT6 receptor antagonists and selective mod-
ulators of TAK1 and cytokine signaling.
5-HT6 receptor antagonists have variable effects on phar-
macological impairments in fear-motivated associative mem-
ory [76–78]. This first study to examine their effect on
neurodevelopmental impairments in this cognitive domain ap-
pears to support some partial reversal worthy of further explo-
ration, in that an isolation-induced deficit was only apparent in
animals that received vehicle and not those treated with the 5-
HT6 receptor antagonist. The locomotor effects of SB-399885
preclude systemic use of higher doses in an attempt to achieve
Fig. 7 Effect of isolation rearing and SB-399885 on cell proliferation
within the dentate gyrus. Mean ± s.e.m. number of Ki-67-positive cells
in the granular cell layer and sub-granular zone, counted from ten evenly
spaced sections per animal. Group-housed (Gr) and isolation-reared (Iso)
male Lister hooded rats received a total of six i.p. injections of vehicle
(1% Tween 80 1 mL/kg) or 10 mg/kg SB-399885 over a 13-day period,
and were killed 24 h after the final injection (n = 6 per group). †P < 0.05
versus the same treatment in group-housed rats (two-way ANOVAwith
Sidak planned multiple post hoc comparisons)
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full reversal of isolation-induced CFR deficits, but alternative
(chronic rather than intermittent) dosing regimens in conjunc-
tion with antipsychotic agents would be valuable for assess-
ment of potential adjunct efficacy. It is worth noting that to
date the only compound to demonstrate full reversal of
isolation-induced deficits in this task is donepezil [79], with
risperidone and an mGluR2/3 agonist both inactive [37, 53].
SB-399885 is anxiolytic at lower doses than used here [38]
and, consistent with this, actually decreases freezing behavior
during contextual fear conditioning [80] perhaps by impairing
consolidation in the dorsal hippocampus [81]. These effects
are in direct opposition to any partial reinstatement of cued
freezing in isolation-reared rats (following a different dosing
schedule) and certainly suggest anxiolytic effects of SB-
399885 are unlikely to confound current CFR data.
Contextual fear memory (which was not modified by
isolation rearing or SB-399885) is hippocampal dependent
[82] and associated with short-term activation of JNK1 and
c-Jun [83], sustained increases in PTEN and TAK1 expres-
sion, and a decrease in PI3K [72]. Cued fear memory is me-
diated by the amygdala [82] and this region therefore repre-
sents a key site for future investigation of 5-HT6 receptor
antagonist-induced signaling alterations.
Expression of Ki-67 positive proliferating cells in the dentate
gyrus granule cell layer is decreased in schizophrenia [84, 85]
and although not a specific neuronal marker the localized de-
crease in known neurogenic regions supports a reduction in
adult neurogenesis, which is in turn suggested to contribute to
hippocampal and cognitive dysfunction in schizophrenia.
Isolation rearing decreases cell proliferation and survival in
the dentate gyrus [86] and the current decrease in Ki-67 further
supports the face validity of the model. 5-HT6 receptor antago-
nists do not appear to enhance neurogenesis in normal adult rats
[87] but the partial reversal of an isolation-induced deficit is
intriguing and should be investigated in combination with an-
tipsychotics, which share some effect on neurogenesis [88].
The most robust alterations in signaling protein expression
in the current study were an isolation-induced increase in total
hippocampal Cdc42 (but a decrease in activation), and region-
specific effects of SB-399885 total TAK1 and MKK4 in
isolation-reared rats. These were accompanied by more subtle
changes in hippocampal TNFα (consistent with another recent
isolation-induced increase [89]) and IL-1β (with the housing
× treatment interaction consistent with a possible immune role
of the 5-HT6 receptor [35]). The underlying mechanism for
isolation-induced cytokine changes has yet to be fully
Fig. 8 Correlations between hippocampal (a, b, d) and frontal cortical (c)
expression of the signaling intermediates or cytokines significantly
influenced by housing and/or treatment, and memory in the novel
object discrimination task (a–c) or cell proliferation within the dentate
gyrus (d). Each data point represents an individual animal; group-housed
and isolation-reared male Lister hooded rats received a total of six i.p.
injections of vehicle (1% Tween 80 1 mL/kg), 5 or 10 mg/kg SB-399885
(lower dose in isolates only) over a 13-day period, and were killed 24 h
after the final injection (n = 11 per group, or n = 6 for Ki-67 expression
following vehicle and the highest dose of SB-399885). *P < 0.05;
**P < 0.01 (Pearson’s r)
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elucidated, but both microglial activation [89] and the gut
microbiome [90] may contribute. Attribution of specific be-
havioral or proliferation readouts to individual signaling alter-
ations requires some caution. It is acknowledged that cell type
or sub-region-specific effects [91, 92] may be masked by the
current analysis of whole hippocampus or frontal cortex ho-
mogenates, and the full range of changes across dynamic sig-
naling cascades may not be captured at a single time point, or
by antibodies unable to differentiate MEK1 from MEK2,
MKK3 from MKK6, and between JNK1–3 isoforms.
Nevertheless, the current study has revealed several alterations
worthy of further research, with an important stating point to
determine whether these back translate from animal models to
human post-mortem tissue. Cdc42 expression within the dor-
solateral prefrontal and anterior cingulate cortices is decreased
in schizophrenia [93–95], potentially due to single nucleotide
polymorphisms [96], and although such changes have not yet
been reported in the hippocampus or other brain regions the
resulting alterations in cortical cytoskeleton dynamics may
underlie spine deficits in layer 3 pyramidal cells [93–95].
Hippocampal Cdc42 activity is implicated throughout adult
neurogenesis, from proliferation of neural progenitor cells,
initial dendrite growth and arborization to spine maturation
[97], and loss of Cdc42 leads to deficits in synaptic plasticity
and memory recall [98]. The pattern of change in the current
study did not appear to mirror isolation-induced deficits in
cognition or Ki67 expression and their reversal (or partial
reversal) by SB-399885 which is somewhat surprising given
that 5-HT6 receptors promote neurite outgrowth in vitro via
activation of Cdc42 [21], however as noted above a more
dynamic insight may be obtained through study of multiple
post-injection time points with a greater level of sub-region
and cell-type specificity. At present specific dysfunction of
neither TAK1 (which phosphorylates JNK via MKK4 and
p38 via MKK3/6) nor MKK4 is implicated schizophrenia,
but there is extensive evidence that downstream alterations
in JNK signaling do contribute [99]. The current alterations
in total TAK1 and MKK4 following six administrations of
SB-399885 to isolation-reared rats over a 13-day period may
be a compensatory adaptation to unexplored signaling chang-
es at earlier time points, and although unlikely to have any
immediate downstream consequence they do impact upon the
pool available for subsequent phosphorylation. Cytokines and
acute physiological stress produce rapid MKK4-JNK activa-
tion in the mouse hippocampus and cortex [100, 101] al-
though to our knowledge the consequences ofmore prolonged
stress for total protein levels have yet to be examined. It is
interesting to note that animals with higher TAK1 and MKK4
expression (and thus potential for higher JNK activation) ex-
hibited worse performance in the NOD task and lower num-
bers of Ki-67 positive proliferating cells in the dentate gyrus; a
general picture consistent with the ability of JNK1 inhibition
to increase neurogenesis [102]. Because TAK1 interacts
directly with many protein products of schizophrenia risk
genes without necessarily being altered itself, it has been pro-
posed as a ‘hub’ within a dysfunctional network and a poten-
tially attractive target via which to restore normal function
[99], although this possibly has yet to be fully explored.
It is noteworthy that the two dose levels of SB-399885
appeared to exert opposing effects on some signaling interme-
diates. The 5-HT6 receptor is expressed on glutamatergic,
GABAergic and to a lesser extent cholinergic neurons [103],
and has been linked to multiple second messengers [14,
16–19], so it is plausible that 5-HT6 receptor ligands could
exert diverging cell type-specific effects through separate
messenger systems. Indeed there is accumulating evidence
that both agonists and antagonists for this receptor exert sim-
ilar behavioral and cognitive effects [104]. One speculation is
that the effects of antagonists are mediated via blockade of 5-
HT-induced GABAergic inhibition (with subsequent gluta-
matergic disinhibition), while agonists might activate a differ-
ent population of 5-HT6 receptors located directly on gluta-
matergic neurones that normally receive little tonic 5-HT input
and so might be relatively unaffected by an antagonist. An
alternative possibility is that ligands acting as antagonists of
one signaling pathway could act as agonists on another [105]
presumably with different minimum effective doses. However
even taking these proposals into consideration there may be a
contradictory effect of SB-399885 on PI3K/Akt signaling,
specifically on the balance between the negative regulator of
this pathway, PTEN, and Akt activation. The main effect of
treatment on PTEN and similar trend for p-Akt (Thr308) both
appear due to small changes in the same direction (decreases
in group-housed rats that received the high dose, and increases
in isolates that received the low dose) rather than the normal
pattern of opposition (only apparent in isolates that received
the high dose). The paradoxical parallel effect, which we ac-
knowledge did not reach robust statistical significance, may
be partly resolved by the stronger influence of SB-399885 on
p-Akt (Thr308) than p-PTEN (Ser380) such that any treatment
effect favors Akt activation, but this appears inconsistent with
the effect of 5-HT6 receptor antagonists on mTOR signaling
[14, 106] and so requires future investigation.
In summary, the current study demonstrates the cognitive
effects of a 5-HT6 receptor antagonist in normal animals are
maintained following post-weaning social isolation. The
available clinical data [107] suggest this neurodevelopmental
model has good predictive validity for schizophrenia, and its
continued use could therefore further elucidate the neurobiol-
ogy and aid assessment of novel therapies for drug-resistant
cognitive symptoms. However, at the single time point studied
here, there was no change in hippocampal expression or phos-
phorylation of JNK or p38 themselves, nor of proteins such as
14-3-3ε, c-Jun, GSK-3β, β-Catenin and HSP90 which have
been associated with schizophrenia and may represent addi-
tional treatment targets [92, 108–111]. Combination of
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isolation rearing with an additional developmental ‘hit’ (such
as maternal immune activation or neonatal PCP administra-
tion [112, 113]) may induce a more complete spectrum of
changes relevant to schizophrenia, including deficits in social
cognition, and future work will evaluate the effect of 5-HT6
receptor antagonists and specific JNK pathway modulators in
such models.
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